Comparative Pharmacology
Head-to-head clinical analysis: K 8 versus KLOR CON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 8 versus KLOR CON.
K+8 vs KLOR-CON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replenishment; corrects hypokalemia by increasing extracellular potassium concentration, restoring membrane potential and cardiac conduction.
Potassium chloride acts as a source of potassium ions, which are essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium is the major cation of intracellular fluid and helps regulate acid-base balance.
40-80 mEq intravenously per day, infusion rate not exceeding 10 mEq/hour; or 20-40 mEq orally 2-4 times daily.
Potassium chloride extended-release: 20-100 mEq per day orally, divided into 2-4 doses, titrated based on serum potassium and clinical response. Usual starting dose: 40 mEq per day.
None Documented
None Documented
Terminal elimination half-life ~2-4 hours (shorter with valproate coadministration, prolonged with renal impairment).
The terminal elimination half-life of potassium is approximately 1-1.5 hours in healthy individuals with normal renal function. In patients with impaired renal function, half-life may be prolonged, increasing the risk of hyperkalemia.
Primarily renal: >90% excreted unchanged by kidneys. Minor fecal (<5%) and negligible biliary elimination.
Renal excretion of potassium ions accounts for approximately 90% of elimination via the kidneys, with the remaining 10% eliminated fecally. No biliary excretion is clinically significant.
Category C
Category C
Potassium Supplement
Potassium Supplement